Showing 1 - 20 results of 23 for search '"Receptor, ErbB-2 immunology"', query time: 4.29s Refine Results
1
Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice

Authors: Franz Buchegger, Leila Bossy, Florence Delie, A. Cirstoiu-Hapca, Robert Gurny, Norbert Lange

Source: Journal of Controlled Release, Vol. 144, No 3 (2010) pp. 324-331

Subject Terms: Pharmaceutical Science, Cancer, medicine.disease, medicine, Monoclonal, Pharmacokinetics, Drug carrier, Biodistribution, Ovarian cancer, Bioluminescence imaging, Pharmacology, Pathology, medicine.medical_specialty, Paclitaxel, chemistry.chemical_compound, chemistry, business.industry, business, ddc:615, ddc:616.0757, Animals, Antibodies, Monoclonal/administration & dosage/pharmacokinetics/*therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phytogenic/administration & dosage/pharmacokinetics/*therapeutic use, Cell Line, Tumor, Drug Carriers/*chemistry, Female, Humans, Mice, Nanoparticles/*chemistry, Ovarian Neoplasms/*drug therapy, Paclitaxel/administration & dosage/pharmacokinetics/*therapeutic use, Receptor, erbB-2/*immunology, Tissue Distribution, Xenograft Model Antitumor Assays

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9620b209f7ff4301c1defc186207bbe
https://doi.org/10.1016/j.jconrel.2010.02.026

2
Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope

Authors: Avgi Mamalaki, Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez, Graham Pawelec, Panagiota A. Sotiropoulou, R Sotiriadou, Hartmut Echner, Susanne Heinzel, Wolfgang Voelter, Angelos D. Gritzapis

Source: British Journal of Cancer
British Journal of Cancer, 85 (10

Subject Terms: Cancer Research, Oncology, MHC class I, biology.protein, biology, Antigen presentation, T cell, medicine.anatomical_structure, medicine, Antigen, Major histocompatibility complex, Epitope, Cytotoxic T cell, MHC class II, Virology, skin and connective tissue diseases, Regular Article, HER-2/neu peptide, CD4+ T cell clones, MHC alleles, vaccines, cancer immunotherapy, Sciences bio-médicales et agricoles, Antigen Presentation, Antigens, Neoplasm -- immunology, Cell Line, Cells, Cultured, Clone Cells, Epitopes, T-Lymphocyte -- immunology, HLA-DR Antigens -- physiology, Humans, Interferon-gamma -- biosynthesis, Lymphocyte Activation, Neoplasms -- immunology, Peptide Fragments -- immunology, Peptides -- immunology, Receptor, erbB-2 -- immunology, T-Lymphocytes, Cytotoxic -- immunology, Tumor Cells, Cultured

File Description: 1 full-text file(s): application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c064cbd2aea380c07af5715e2ac6a1
https://doi.org/10.1054/bjoc.2001.2089

PDF Full Text
8
Electronic Resource
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

Source: Targeted oncology, 4 (2

Index Terms: Sciences bio-médicales et agricoles, Adjuvants, Immunologic -- administration & dosage, Anthracyclines -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal -- adverse effects, Breast Neoplasms -- immunology, Breast Neoplasms -- mortality, Breast Neoplasms -- pathology, Breast Neoplasms -- physiopathology, Breast Neoplasms -- therapy, Drug Resistance, Neoplasm, Female, Heart Failure -- chemically induced, Humans, Oxidative Stress, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- adverse effects, Quinazolines -- administration & dosage, Quinazolines -- adverse effects, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Receptor, erbB-2 -- antagonists & inhibitors, Receptor, erbB-2 -- immunology, Survival Rate, Ventricular Outflow Obstruction -- chemically induced, Anti-HER-2 therapies, Breast cancer, Cardiotoxicity, Lapatinib, Trastuzumab, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article

URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/52366
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL

9
Electronic Resource
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

Source: Targeted oncology, 4 (2

Index Terms: Sciences bio-médicales et agricoles, Adjuvants, Immunologic -- administration & dosage, Anthracyclines -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal -- adverse effects, Breast Neoplasms -- immunology, Breast Neoplasms -- mortality, Breast Neoplasms -- pathology, Breast Neoplasms -- physiopathology, Breast Neoplasms -- therapy, Drug Resistance, Neoplasm, Female, Heart Failure -- chemically induced, Humans, Oxidative Stress, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- adverse effects, Quinazolines -- administration & dosage, Quinazolines -- adverse effects, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Receptor, erbB-2 -- antagonists & inhibitors, Receptor, erbB-2 -- immunology, Survival Rate, Ventricular Outflow Obstruction -- chemically induced, Anti-HER-2 therapies, Breast cancer, Cardiotoxicity, Lapatinib, Trastuzumab, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article

URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/52366
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL

Search Tools: Get RSS Feed — Email this Search